Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Interest & Investment Income (2016 - 2025)

Ironwood Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 87.53% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $4.1 million, down 8.77%, while the annual FY2025 figure was $4.1 million, 8.77% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.5 million at Ironwood Pharmaceuticals, up from $930000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $8.8 million in Q2 2023 and bottomed at $172000.0 in Q2 2021.
  • The 5-year median for Interest & Investment Income is $1.1 million (2022), against an average of $1.9 million.
  • The largest annual shift saw Interest & Investment Income surged 3061.74% in 2023 before it crashed 84.37% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $180000.0 in 2021, then surged by 2925.56% to $5.4 million in 2022, then plummeted by 78.08% to $1.2 million in 2023, then tumbled by 34.84% to $778000.0 in 2024, then skyrocketed by 87.53% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Interest & Investment Income are $1.5 million (Q4 2025), $930000.0 (Q3 2025), and $818000.0 (Q2 2025).